837376-36-0

Basic information

• Product Name: Tolterodine hydrobromide
• Synonyms: 2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol hydrobromide;Tolterodine hydrobromide;2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol hydrobromide [(Tolterodine hydrobromide];N,N-diisopropyl-3-(2-hydroxy-5-Methylphenyl)-3-phenylpropylaMine HydrobroMide;Tolterodine HydrobroMide RaceMate;(R)-2-(3-(Diisopropylamino)-1-phenylpropyl)-4-methylphenol hydrobromide;N,N-Diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropan-1-amine hydrobromide racemate
• CAS NO: 837376-36-0
• Molecular Formula: BrH*C₂₂H₃₁NO
• Molecular Weight: 406.4
• Mol File: 837376-36-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 473ºC at 760 mmHg
• Flash Point: 239.9ºC
• Appearance: /
• Vapor Pressure: 1.44E-09mmHg at 25°C
• CAS DataBase Reference: Tolterodine hydrobromide(CAS DataBase Reference)
• NIST Chemistry Reference: Tolterodine hydrobromide(837376-36-0)
• EPA Substance Registry System: Tolterodine hydrobromide(837376-36-0)

Safety Data

• Hazardous Substances Data: 837376-36-0(Hazardous Substances Data)

Usage

General Description

Tolterodine hydrobromide is a chemical compound used in the treatment of overactive bladder and urinary incontinence. It works by blocking the acetylcholine receptors in the bladder, leading to a decrease in involuntary contractions of the bladder muscles. This helps to reduce the frequency and urgency of urination. Tolterodine hydrobromide is available in various forms such as tablets, extended-release capsules, and an oral suspension. It is generally well-tolerated, with common side effects including dry mouth, constipation, and blurred vision. However, it may not be suitable for individuals with certain medical conditions such as gastric retention, uncontrolled narrow-angle glaucoma, or severe ulcerative colitis. It is important to consult a healthcare professional before using tolterodine hydrobromide to determine if it is the appropriate treatment option.

InChI:InChI=1/C22H31NO.BrH/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24;/h6-12,15-17,20,24H,13-14H2,1-5H3;1H/t20-;/m1./s1

Upstream product

• 140-10-3 (E)-3-phenylacrylic acid 
• 40546-94-9 6-methyl-4-phenyl-3,4-dihydrocoumarin 
• 108-18-9 diisopropylamine 
• 106-44-5 p-cresol 
• 173948-30-6 (E)-N,N-diisopropyl-3-phenylprop-2-en-1-amine 
• 124935-89-3 N-diisopropyl-3-(2-methoxy-5-methylphenyl)-3-phenylpropanamine hydrogen fumarate 
• 124935-88-2 N,N-diisopropyl-3-(2-methoxy-5-methylphenyl)-3-phenylpropan-1-amine 

Downstream Products

• 389068-22-8 N,N-diisopropyl-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropylamine 
• 124936-74-9 N,N-diiso-propyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine 
• 124937-52-6 tolterodine tartrate 
• 209747-05-7 tolterodine tartrate 

Relevant articles and documents

Design, Synthesis, and Molecular Modeling of Asymmetric Tolterodine Derivatives as Anticancer Agents

An efficient and short enantioselective synthesis of (S)- and (R)-tolterodine acid isomers (7a–7i) was performed a 6-methyl-4-phenylchroman-2-one intermediate from inexpensive and commercially available starting materials. A series of tolterodine acid hyb

METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES

The invention relates to a method of obtaining 3,3-diphenylpropylamines (I), wherein R1 is H, alkyl, haloalkyl or alkoxyalkyl, R2 is alkyl, alkoxy, halogen, NO2, CN, CHO, which may be free or protected, CH2OH or COOR6, and R3 and R4 are selected independently from H and alkyl or together with the nitrogen to which they are bound form a ring having 3 to 7 members. The inventive method consists in reacting a propylenephenylamine and a disubstituted aromatic hydrocarbon and, if necessary, separating the desired enantiomer or the mixture of enantiomers, and/or converting the compound (I) into a salt. Compounds (I) are muscarinic receptor antagonists which can be used in the treatment of urinary incontinence and other symptoms of urinary bladder hyperactivity. Said compounds include tolterodine.

METHOD OF OBTAINING TOLTERODINE

The process comprises reacting a compound of formula (II), where R is a hydroxyl protecting group, and the asterisk indicates an asymmetric carbon atom, with diisopropylamine in the presence of a reducing agent; optionally converting the resulting intermediate into a salt and, if so desired, isolating it; removing the hydroxyl protecting group; and if so desired, separating the desired (R) or (S) enantiomer, or the mixture of enantiomers and/or converting the obtained compound into a pharmaceutically acceptable salt thereof. Tolterodine is a muscarinic receptor antagonist useful in treating urinary incontinence and other symptoms of urinary bladder hyperactivity.